The aim of this study was to evaluate the relationship between final height (FH),relative FH gain (FH-TH) and GH secretion before and after GH therapy in children.We studied 72 short children [chronological age (CA):11.1±2.2 yrs; height (H):-2.0±0.4; height for bone age (HBA):-0.6 ±1.1; target height (TH):-1.1±0.8] with GH peaks <10 ng/ml after 2 pharmacological stimulation tests. 53/72 showed the mean nocturnal GH concentration (MGHC) <3 ng/ml and 19/72 ≥3 ng/ml. All pts. were treated for 4-5 yrs with GH (7mg/m²/wk). GH secretion was re-tested at FH (the MGHC was re-evaluated only in 12/53 with previous MGHC<3 ng/ml). 42 children with normal GH secretion and clinically similar to the GH treated pts. were followed until FH as control group (CG).The parameters were expressed in SDS. First evaluation: FH and FH-TH (-1.1±0.9; 0.0±0.1) in GH treated pts. were both higher (p

Final Height Related to Growth Hormone Levels (Stimulated and Physiological) Evaluated in Short Children Before and After Growth Hormone Therapy

PIRAZZOLI, PIERO;BARONIO, FEDERICO;ZUCCHINI, STEFANO;GUALANDI, STEFANO;PASINI, ANDREA;CASSIO, ALESSANDRA;SALARDI, SILVANA;CICOGNANI, ALESSANDRO;CACCIARI, EMANUELE
2004

Abstract

The aim of this study was to evaluate the relationship between final height (FH),relative FH gain (FH-TH) and GH secretion before and after GH therapy in children.We studied 72 short children [chronological age (CA):11.1±2.2 yrs; height (H):-2.0±0.4; height for bone age (HBA):-0.6 ±1.1; target height (TH):-1.1±0.8] with GH peaks <10 ng/ml after 2 pharmacological stimulation tests. 53/72 showed the mean nocturnal GH concentration (MGHC) <3 ng/ml and 19/72 ≥3 ng/ml. All pts. were treated for 4-5 yrs with GH (7mg/m²/wk). GH secretion was re-tested at FH (the MGHC was re-evaluated only in 12/53 with previous MGHC<3 ng/ml). 42 children with normal GH secretion and clinically similar to the GH treated pts. were followed until FH as control group (CG).The parameters were expressed in SDS. First evaluation: FH and FH-TH (-1.1±0.9; 0.0±0.1) in GH treated pts. were both higher (p
2004
163
163
P. Pirazzoli; F. Baronio; S. Zucchini; S. Gualandi; A. Pasini; A. Cassio; S. Salardi; A. Cicognani; E. Cacciari
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/26220
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact